Research ArticleFeatured Articles

Nonalcoholic Fatty Liver Disease from the Perspective of an Internist

Satheesh Nair
Ochsner Journal March 2002, 4 (2) 92-97;

References

  1. ↵
    1. Ludwig J.,
    2. Viggiano T. R.,
    3. McGill D. B.
    (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438, pmid:7382552.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Day C. P.,
    2. James O. F.
    (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845, pmid:9547102.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Reid A. E.
    (2001) Nonalcoholic steatohepatitis. Gastroenterology 121:710–723, pmid:11522755.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Weltman M. D.,
    2. Farrell G. C.,
    3. Liddle C.
    (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645–1653, pmid:8942745.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Weltman M. D.,
    2. Farrell G. C.,
    3. Hall P.
    (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128–133, pmid:9425928.
    OpenUrlCrossRefPubMedWeb of Science
    1. Wigg A. J.,
    2. Roberts-Thomson I. C.,
    3. Dymock R. B.
    (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206–211, pmid:11156641.
    OpenUrlAbstract/FREE Full Text
    1. Berson A.,
    2. DeBeco V.,
    3. Letteron P.
    (1998) Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764–774, pmid:9516397.
    OpenUrlCrossRefPubMedWeb of Science
    1. Nair S.,
    2. Cope K.,
    3. Risby T. H.
    (2001) Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 96:1200–1204, pmid:11316170.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Powell E. E.,
    2. Cooksley W. G.,
    3. Hanson R.
    (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80, pmid:2295475.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Clark J. M.,
    2. Brancati F.,
    3. Diehl A. M.
    (2001) Non alcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population. Gastroenterology 120:A65.
    OpenUrl
  11. ↵
    1. Wanless I. R.,
    2. Lentz J. S.
    (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106–1110, pmid:2227807.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Bellentani S.,
    2. Saccoccio G.,
    3. Masutti F.
    (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112–117, pmid:10644271.
    OpenUrlPubMedWeb of Science
  13. ↵
    1. Poonawala A.,
    2. Nair S.,
    3. Thuluvath P. J.
    (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32:689–692, pmid:11003611, (4 Pt 1).
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Caldwell S. H.,
    2. Oelsner D. H.,
    3. Iezzoni J. C.,
    4. Hespenheide E. E.,
    5. Battle E. H.,
    6. Driscoll C. J.
    (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664–669, pmid:10051466.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Charlton M.,
    2. Kasparova P.,
    3. Weston S.
    (2001) Frequency of non-alcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7:608–614, pmid:11460228.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Matteoni C. A.,
    2. Younossi Z. M.,
    3. Gramlich T.
    (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413–1419, pmid:10348825.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Dixon J. B.,
    2. Bhathal P. S.,
    3. O'Brien P. E.
    (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100, pmid:11438497.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Nair S.,
    2. Eason J. D.,
    3. Loss G. E.
    (2001) Relative Risk of Hepatocellular Carcinoma in Cirrhosis due to Fatty Liver Disease: A Study Based on Incidental Hepatocellular Carcinoma in Liver Transplant Recipient. Hepatology 34:462A.
    OpenUrl
  19. ↵
    1. Murata Y.,
    2. Ogawa Y.,
    3. Saibara T.
    (2000) Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7:1299–1304, pmid:11032933.
    OpenUrlPubMed
  20. ↵
    1. Lin H. Z.,
    2. Yang S. Q.,
    3. Chuckaree C.
    (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998–1003, pmid:10973319.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Marchesini G.,
    2. Brizi M.,
    3. Bianchi G.
    (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358:893–894, pmid:11567710.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Caldwell S. H.,
    2. Hespenheide E. E.,
    3. Redick J. A.
    (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519–525, pmid:11232700.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Abdelmalek M. F.,
    2. Angulo P.,
    3. Jorgensen R. A.
    (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96:2711–2717, pmid:11569700.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Laurin J.,
    2. Lindor K. D.,
    3. Crippin J. S.
    (1996) Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464–1467, pmid:8675165.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Hasegawa T.,
    2. Yoneda M.,
    3. Nakamura K.
    (2001) Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15:1667–1672, pmid:11564008.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Lavine J. E.
    (2000) Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136:734–738, pmid:10839868.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Contos M. J.,
    2. Cales W.,
    3. Sterling R. K.
    (2001) Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7:363–373, pmid:11303298.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section